Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Trial

Sponsor
Tuen Mun Hospital
Study ID
NCT01718951
Phase
PHASE4
Status
Completed

Conditions

  • Spondyloarthropathy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • golimumab — DRUG
    golimumab
  • Pamidronate — DRUG
    pamidronate

Study Details

To compare the efficacy of golimumab with pamidronate in the treatment of axial spondyloarthropathy

Key Dates

Start date
Aug 31, 2012
Status verified
May 2015
Primary completion
Mar 31, 2014
Completion
Oct 31, 2014

Study Design

Enrollment
30 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: golimumab
    golimumab 50mg subcutaneous every 4 weeks
  • Active Comparator: pamidronate
    Pamidronate (60mg) intravenously every 4 weeks

Primary Outcome Measure

Assessment of SpondyloArthritis international Society criteria (ASAS)-20 response response [ Time Frame: week 48 ]